Figure 2. TTF1 and MYC are single biomarkers of response to multiple drugs.
A. Supervised comparison of NKX2-1, ASCL1 MYC and NEUROD1 expression in George et al. patient tumors (sorted by NKX2-1 expression, p-values for correlation to NKX2-1). B. Comparison of mean drug sensitivities (relative IC50) between the two subsets shows Group 2 (TTF1 low) cell lines to be more sensitive to a number of targeted agents. C. Drug-target constellation (DTECT) maps of drugs differentially sensitive between TTF1 high and low cell lines (FC >3.0, p < 0.01). Drugs with differential sensitivity are mapped by their primary, secondary and tertiary targets. Underlined drugs are either FDA approved or licensed for use in Canada/Europe. D. Density plot of TTF1 expression mapped to expression of cMYC, NKX2-1, MYC and sensitivity to selected drugs (relative IC50’s) in cell lines. p-values from Spearman correlation between TTF1 expression and IC50.